Incyte Bolsters Dermatology Ambitions With Vitiligo Approval For Topical Ruxolitinib
Opzelura, already approved for atopic dermatitis, gives Incyte a second indication for its topical JAK inhibitor. It is the first treatment approved for vitiligo.
You may also be interested in...
The FDA approved baricitinib for the hair loss disorder despite safety concerns with JAK inhibitors. It carries the same warnings on risk of CV events and malignancy as the others in the class.
As it prepares to file lebrikizumab for atopic dermatitis, the Spanish group is looking to expand into vitiligo through a collaboration with France’s Inserm Transfert to develop topical therapies for the condition where pale patches develop on the skin caused by the lack of melanin.
Ahead of pending regulatory decisions on both sides of the Atlantic for Opzelura, Incyte has reported promising progress for the JAK inhibitor in the highly competitive atopic dermatitis market.